Belgian telcos: Telenet small positive net adds, good financials, guidance up. Kinepolis: US Cinemark strong, 5% growth in US tickets, consumption per visitor. KPN: VodafoneZiggo 2Q25 very weak, guidance maintained. PostNL: 2Q25 beats underlying slightly; FY25 guidance reiterated, EU court appeal
argenx reported 1H25 results today, with Vyvgart sales showing a solid CSS beat. In this note you can find our main takeaways from the conference call. ARGX-119 phase 3 in CMS - argenx emphasized that they currently have 3 assets in phase 3 development with the advancement of ARGX-119 to phase 3 in Congenital Myasthenic Syndrome (CMS). ARGX-119 targets MuSK in the neuromuscular junction and is advanced in CMS, an ultra-rare disease. This allows for a small trial with dense monitoring of patients...
argenx reported another strong quarter with Vyvgart sales coming in at $ 949m, beating CSS by approx. 10%. argenx reached operating profitability for the 4th consecutive quarter, and is on track for FY25 profitability. Pipeline timelines are reiterated and we look ahead to the upcoming readouts in seronegative gMG (2H25), as well as PoC results in lupus nephritis (Vyvgart, 4Q25) and delayed graft function (empa, 2H25). ARGX-119 R&D day set for 16 September. Accumulate/ € 670 TP reiterated.
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update $949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional topline data readouts across pipeline remain on track for second half of 2025 Management to host conference call today at 2:30 PM CET (8:30 AM ET) July 31, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a gl...
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025 July 24, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx...
ASM: 2Q25 Preview, AI winner BE Semiconductor Industries: 2Q25 Preview, focus on advanced order intake CM.com: Preview 1H25 D'Ieteren: Belron $4.655bn TBL repriced 25bp lower PostNL: Preview 2Q25F; consensus released Wolters Kluwer: To divest Finance, Risk and Regulatory Reporting unit
Since the last publication of our Dynamic Top Pick List on 5 June 2025, our selection has seen again a nice outperformance versus the reverence indices (AEX, Bel20 and Eurostoxx50) of on average 3.3%. Our July update brings 3 adjustments to the list : Since being added to the list in December 2024, Fagron's share price has surged +/-22%, driven by strong Q1 2025 results and robust growth across all regions. Fagron reaffirmed its FY25 guidance and unveiled its “Compounding for Growth” strategy, ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.